[Clinical evaluation on the usefulness of 5,7-dichloro-8-hydroxyquinoline (chloroxine) in association with betamethasone 17-benzoate in the topical treatment of infected cortisone-sensitive dermopathies].
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D001623:Betamethasone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D002739:Chloroquinolinols / Q000008:administration & dosage*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004485:Eczema / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006912:Hydroxyquinolines / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013290:Streptococcal Infections / Q000188:drug therapy*
D002739:Chloroquinolinols; D006912:Hydroxyquinolines; C004357:chloroxine; C015706:betamethasone benzoate; D001623:Betamethasone
Valutazione clinica sull'utilià dell'impiego del 5,7-dicloro-8-idrossichinolina (clorossina) in associazione con il betametasone 17-benzoato nel trattamento topico di dermopatie cortisonosensibili infette.